Tvardi Therapeutics
NASDAQ: TVRDHouston, US · Founded 2017 · Delaware corporation · 20 employees on LinkedIn · 1 known investors
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule STAT3 inhibitors to treat inflammatory and proliferative diseases. Its pipeline includes TTI-101, a direct STAT3 inhibitor in a Phase 2 trial for hepatocellular carcinoma, and TTI-109, a phosphate prodrug of TTI-101.
Founders & leadership
Tvardi Therapeutics was founded in 2017 by David J. Tweardy.
DJ
David J. TweardyFounder
RD
Ronald DePinhoNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$78.1M disclosed across 2 rounds · 2018–2021
▶$72.4MraisedJun 2021 · 32 investors · BiotechnologyRule 506(b)
▶$72.4MraisedJun 2021 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jamie McNabDirector
- Michael WyzgaDirector
- Wallace HallDirector
- Imran AlibhaiExecutive Officer, Director
- Sujal ShahDirector
- Offering amount
- $75.1M
- Amount sold
- $72.4M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.6MraisedJul 2018 · 8 investors · PharmaceuticalsRule 506(b)
▶$5.6MraisedJul 2018 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ronald DePinhoDirector
- David J. TweardyExecutive Officer, Director
- Offering amount
- $8.5M
- Amount sold
- $5.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapViridian Therapeutics32 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Robinhood23 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Public19 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Simply Wall St19 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
TradingView18 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with Tvardi Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Tvardi Therapeutics do?
- Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule STAT3 inhibitors to treat inflammatory and proliferative diseases. Its pipeline includes TTI-101, a direct STAT3 inhibitor in a Phase 2 trial for hepatocellular carcinoma, and TTI-109, a phosphate prodrug of TTI-101.
- Who founded Tvardi Therapeutics?
- Tvardi Therapeutics was founded by David J. Tweardy in 2017.
- Who are Tvardi Therapeutics's investors?
- Tvardi Therapeutics's investors include Solas BioVentures.
- How much funding has Tvardi Therapeutics raised?
- Tvardi Therapeutics has disclosed $78.1M raised across 2 rounds.
- Where is Tvardi Therapeutics headquartered?
- Tvardi Therapeutics is headquartered in Houston, US.